Capricor Therapeutics
Capricor Therapeutics is a biotechnology company focused on developing transformative cell and exosome-based therapeutics for muscular and other diseases. Their lead candidate, deramiocel (CAP-1002), is in Phase 3 clinical development for Duchenne muscular dystrophy. The company also develops exosome technology as a next-generation therapeutic platform, aiming to deliver nucleic acids and proteins to treat or prevent various diseases. They are engaged in clinical trials, regulatory updates, and have a pipeline of innovative therapies.
Industries
Nr. of Employees
medium (51-250)
Capricor Therapeutics
Products
Allogeneic cardiosphere-derived cell therapy candidate
An allogeneic cell therapy candidate derived from cardiosphere-derived cells, developed for treatment of Duchenne muscular dystrophy and advanced into late-stage clinical evaluation.
Engineered exosome therapeutic platform
A development platform focusing on engineered exosomes intended to deliver defined nucleic acids and proteins for therapeutic applications across multiple indications.
Deramiocel
Capricor's core therapeutic technology comprised of cardiosphere-derived cells (CDCs), an endogenous population of stromal cells derived from human hearts with anti-inflammatory, anti-fibrotic, and immunomodulatory properties.
CDC-Exosomes
Cardiosphere-derived cell exosomes being evaluated for the treatment of Duchenne muscular dystrophy.
StealthX
A proprietary exosome platform focused on vaccinology and the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics.
Allogeneic cardiosphere-derived cell therapy candidate
An allogeneic cell therapy candidate derived from cardiosphere-derived cells, developed for treatment of Duchenne muscular dystrophy and advanced into late-stage clinical evaluation.
Engineered exosome therapeutic platform
A development platform focusing on engineered exosomes intended to deliver defined nucleic acids and proteins for therapeutic applications across multiple indications.
Deramiocel
Capricor's core therapeutic technology comprised of cardiosphere-derived cells (CDCs), an endogenous population of stromal cells derived from human hearts with anti-inflammatory, anti-fibrotic, and immunomodulatory properties.
CDC-Exosomes
Cardiosphere-derived cell exosomes being evaluated for the treatment of Duchenne muscular dystrophy.
StealthX
A proprietary exosome platform focused on vaccinology and the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics.
Services
Partnerships with external organizations for co-development of cell- and exosome-based therapeutics, including shared preclinical and clinical programs.
Policy-driven program coordination to evaluate and manage expanded access / compassionate use requests in accordance with an established company policy.
Partnerships with external organizations for co-development of cell- and exosome-based therapeutics, including shared preclinical and clinical programs.
Policy-driven program coordination to evaluate and manage expanded access / compassionate use requests in accordance with an established company policy.
Expertise Areas
- Cell therapy development (allogeneic)
- Exosome and extracellular vesicle therapeutics
- Clinical trial design and management
- CMC and biologics manufacturing scale-up
Key Technologies
- Exosome / extracellular vesicle engineering
- Allogeneic cell therapy (cardiosphere-derived cells)
- Nucleic acid and protein delivery via extracellular vesicles
- Biologics manufacturing and CMC processes